Dr Doussou Touré arrives for work at Coléah Medical Centre. She washes her hands from a bucket set up in front of the building, proceeds to a screening area where her temperature is checked and recorded and only then enters the bustling facility that she supervises.
“Ebola is under control now, but we try to keep up the infection prevention and control systems that were put in place during the outbreak,” Dr Touré says, pointing to several sturdy, brightly-coloured bins, each one designated for the disposal of varying waste matter.
On April 2, the United to Combat Neglected Tropical Diseases: A Conversation on Progresswebcast and live Q&A will be broadcast live from Institut Pasteur in Paris from 18:00 - 19:30 Central European Time/12:00 - 13:30 Eastern Standard Time.
Imagine if clinics in developing countries were equipped with an inexpensive yet durable tool that could help medical personnel identify and diagnose a variety of deadly diseases like Malaria, Chagas disease, or Leishmaniosis? For millions of people around the world waiting to be diagnosed and treated, such a tool could be a life-saver.
The HOOKVAC consortium, a global consortium led by the University of Amsterdam’s Academic Medical Center, recently announced an $8.16 million grant to develop and test a vaccine for human hookworm.
The grant from the European Commission FP7 program will expand the work of the Sabin Vaccine Institute Product Development Partnership to begin the first clinical testing of human hookworm vaccine in the West African nation of Gabon.